Copyright
©The Author(s) 2022.
World J Hepatol. Aug 27, 2022; 14(8): 1562-1575
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1562
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1562
Response to treatment mRECIST | Stationary, n = 4 (5.7%) | Partial response, n = 7 (10.0%) | Complete response, n = 34 (48.6%) | Progressive disease, n = 6 (8.6%) | P value |
miRNA-326 | 11.5 (2.1- 142.6) | 31.1 (6.9- 209.4) | 27.4 (10.0- 155.2) | 69.6 (17.7- 197.9) | 0.5 |
miRNA-511 | 3.8 (0.8- 10.5) | 1.2 (0.3- 4.2) | 1.0 (0.2- 1.5) | 0.6 (0.1- 1.3) | 0.05a |
miRNA-424 | 4.9 (3.0- 8.6) | 4.8 (2.1- 5.1) | 5.4 (2.6- 13.1) | 4.6 (3.1- 15.2) | 0.8 |
- Citation: Youssef SS, Elfiky A, Nabeel MM, Shousha HI, Elbaz T, Omran D, Marie MS, Elzahry MA, Abul-Fotouh A, Hashem A, Guda MF, Abdelaziz AO. Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians. World J Hepatol 2022; 14(8): 1562-1575
- URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1562.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1562